GlassScriptPhysician profile
Philip A Roth
NPI 1710968383
$6,031.08
in general payments reported to CMS, 2019-2025
49 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $888 · 2021: $930 · 2022: $1,112 · 2023: $1,245 · 2024: $877 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.56 | 2019-2024 | Ubrelvy, Vraylar, Synthroid |
| Lilly USA, LLC | $578.93 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $507.32 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $462.24 | 2019-2021 | |
| Amgen INC. | $402.05 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.80 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $255.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceuticals, INC. | $250.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $246.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $234.72 | 2021-2025 | |
| Pfizer INC. | $195.05 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $190.01 | 2024-2025 | Voquezna |
| Medicure Pharma INC. | $184.60 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.65 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $115.61 | 2023-2025 | Gemtesa |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.